zurück

Tofacitinib (new indication: ankylosing spondylitis)

Subject:

  • Active Substance: Tofacitinib
  • Name: Xeljanz®
  • Therapeutic area: Ankylosing spondylitis
  • Pharmaceutical company: Pfizer Pharma GmbH

Time table:

  • Start: 15.12.2021
  • Final decision by G-BA: 16.06.2022

Final decision:

  • a1) Adult patients who have had an inadequate response to conventional therapy: No additional benefit proved
  • a2) Adult patients who have had an inadequate response to, or intolerance to, prior biologic antirheumatic drug (bDMARD) therapy: No additional benefit proved